Summary of overall treatment effects and clinical feedback of Larotrectinib

Larotrectinib is a highly selective TRK inhibitor, mainly used to treat patients with solid tumors with NTRK gene fusions. Unlike traditional chemotherapy and some targeted drugs, larotrectinib breaks through the traditional thinking of "dividing treatment according to tumor origin". Its clinical indications are based on molecular characteristics rather than cancer types, which is a milestone in the history of the development of precision medicine. Since the advent of this drug, multiple domestic and foreign clinical studies and real-world use experience have shown that larotrectinib can demonstrate high objective response rates and durable disease control in patients of different ages and tumor types. Therefore, the overall therapeutic effect has been widely recognized by the academic community.

In pivotal studies, larotrectinib demonstrated impressive objective response rates. Taking a multi-center Phase II clinical trial covering adults and children as an example, among the treated NTRK fusion-positive patients, the objective response rate exceeded 75%, and some patients even achieved complete remission. The median duration of response exceeds 35 months and the median progression-free survival exceeds 25 months, which is extremely rare in highly progressive and drug-resistant solid tumors. It is particularly worth noting that this effect is not limited to specific cancer types. Patients may benefit from common non-small cell lung cancer and thyroid cancer, as well as rare salivary gland cancer and sarcoma. This "pan-cancer" effect makes larotrectinib a representative drug in the context of precision medicine.

In terms of clinical feedback, larotrectinib not only has accurate efficacy during actual use, but also has a controllable safety profile. Most patients experience mild to moderate side effects during taking the drug, such as fatigue, dizziness, gastrointestinal discomfort, and slight elevation of aminotransferases. Compared with chemotherapy and some other targeted drugs, the overall incidence of side effects of larotrectinib is lower, and the proportion of serious adverse reactions is less than 20%. The drug has also been shown to be well tolerated in pediatric patients, with parents and doctors generally reporting that their children's quality of life has been significantly improved, allowing them to go to school and participate in daily activities. This advantage makes it particularly valuable in the treatment of rare tumors in children. In addition, some long-term follow-up cases show that after receiving larotrectinib treatment, patients not only effectively controlled the tumor burden, but even experienced long-term remission, providing new hope for prolonging survival and improving quality of life.

In general, the therapeutic effect of larotrectinib is consistent with clinical feedback, that is, it can bring significant efficacy in different tumor types and different populations, and maintain good safety. This feature makes it one of the preferred treatment options for NTRK fusion-positive patients. Despite this, some patients will still develop drug resistance during long-term treatment. Common mechanisms include secondary mutations in the kinase domain of TRK. For these situations, there is currently a second generationTRKInhibitors are being developed to overcome resistance and prolong patient benefit. Judging from the overall data and clinical feedback, larotrectinib not only breaks through the limitations of traditional treatments in terms of efficacy, but also actually improves the prognosis and living conditions of patients in practice. With the popularization of detection technology, more NTRK fusion-positive patients will be screened, which also provides greater space and value for the widespread application of larotrectinib.

Reference materials:https://www.drugs.com/